Key learning points:
- Patients with COPD may also suffer from other conditions, such as anxiety disorders, cardiac disease or diabetes
- Tobacco smoking is recognised as the most common cause of COPD, so smoking cessation may be one way of successfully managing the condition
- Between 20% and 50% of COPD patients are non-adherent, the main problem being misunderstanding medication
Chronic obstructive pulmonary disease (COPD) is recognised as one of the most common respiratory diseases in the UK, with over 5 million people diagnosed.[1,2] Maintaining ‘quality of life’ is dependent on a range of care, including prescribed medication. However, studies from the 1990s and more recent research identify that those diagnosed with COPD often struggle to manage their medication due to a range of health-related problems.
COPD co-morbidities can comprise a range of conditions such as anxiety disorders or those of organ function, for example cardiac disease or diabetes. However, the management of the co-morbidity can also affect the person’s COPD and vice versa. These further complexities add to the overall pharmacological burden. Moreover, there is little guidance for the health professional on the most appropriate choice of medication delivery.
Medication compliance and adherence is a major component in COPD care. The nurse is key in screening and monitoring these patients and the role is recognised as increasingly important in supporting the role of the physician and providing continuity of care [4,5] – in particular health promotion and patient education. The community nurse is often able to view at first hand some of the COPD patient’s daily challenges, which may shed light on reasons for non-compliance.
It is recognised that suboptimal medication levels impact adversely on the patient and also generally on healthcare expenditure. Braido et al  identified compliancy as something that involves a definite decision on the part of the person to accept their condition and their management.
However, the issues surrounding COPD as a whole can be complex. In the arena of poor compliance, a whole raft of other elements may be identified, such as personal limitations caused by the disease – ageing processes, poor cognition abilities, anxiety states and depression. Other factors may include a reduced belief in the efficacy of the medication, underestimation of the severity of the condition and tobacco smoking.
Tobacco smoking is recognised as the commonest cause of COPD. The evidence for nurse-led smoking cessation programmes has shown positive results. However, for many people smoking is part of their social construct; an activity that provides pleasure, relaxation and helps relieve tension. Therefore, successfully managing COPD may include a person making multiple lifestylechanges such as smoking cessation and starting an exercise regime as well as medication adherence – but this may be hard to achieve in some.
Studies from the late 1990s demonstrated that up to 90% of patients with inhaled medications were not using their inhaler devices correctly.[13,14]
Dry powder inhalers (DPIs) and pressurised metered dose inhalers (pMDIs) are the most commonly used delivery systems for dispensing aerosol drugs and are recommended at all stages of treatment. Worldwide they are the most frequently prescribed device, and are considered the cornerstone of COPD management. These plus adjunctive therapies such as smoking cessation and oxygen and drug therapy have long been recognised as mainstays of COPD treatment.[16,17]
However, the management of COPD is multifaceted, due to the long-term and changing nature of the disease, which can also include periods of remission. Also, COPD is often associated with multiple comorbidities, which may require other medications, administered by varying routes.
Furthermore, differing disease combinations can prompt changes to medication regimes – which can influence an individual’s adherence.
COPD is a long-term condition and a study by the WHO in 2003 estimated that there is a 50% adherence or less for patients taking medications over a long period, with the improper use of medication being more frequent in those over 65, especially when coupled with polypharmacy. Prescribing appropriately and accommodating some of the problems faced by patients requires a holistic assessment to identify potential problems that may affect adherence. However, there is little advice on inhaler selection in prescribing guidelines.
Therefore the primary focus could be on medication choice, not the patient’s ability to use the inhaler.
Between 20% and 50% of patients with COPD are considered to be non-adherent. The main problem is medication being underused.[22,23] There is also the problem of polypharmacy and improper use of medication delivery, which increases in patients over 65. Problems include a lack of understanding of how the medication device functions, incorrect inhaler technique and difficulties in handling the inhaler, which may be attributable to poor co-ordination between inspiration and inhaler activation. A combination of these elements is considered to be particularly common in the older age group or those with advanced lung damage.
The inhalation force is another major aspect in compliance. Manufacturers recommend a ‘deep and hard’ inhalation, which allows a fast acceleration rate and allows the formulation of the metered dose to break into particles that enter the inspired airstream and deposit in the lungs. However, the level of resistance in the inhaler device, coupled with the level of COPD obstruction can affect the rate of flow. Therefore, patients with severe COPD are not always able to achieve fast inhalation rates. Incorrect use of pMDIs, especially in those not using a spacer, and failure to co-ordinate inspiration with actuation results in a reduced deposition in the lung.
A significant correlation has been identified between a patient’s satisfaction with their device and their level of compliance. A poor inhaler technique has been linked to increased use of reliever medication and also to a rise in the use of emergency services, which demonstrates the importance of patient support and good technique.[27,28]
A change in device can also be a cause of poor compliance. With this in mind, the European Respiratory Society has recommended that patients remain on their current inhaler regime if their disease is stable.
The nurse’s role
The primary care nurse has an important role in supporting the patient at all stages from initial diagnosis to end-of-life care. However, although the literature contains information on the reactive aspects of COPD care, there is little about proactive management. It has been noted that health professionals may fail to recognise non-adherence and might instead attribute symptom changes to other causes.
This is not surprising, as COPD can be highly complex and encompass periods of exacerbation and remission. In many cases, the symptoms might include mental health problems such as depression.
The literature supports the view that ’strong’ education initiatives enable patients to manage their medication more effectively.
However, due to the changing nature of COPD, it could be considered that some medication regimes can be just as complex as the condition itself.
In 2008, the Department of Health made a case in its paper the NHS Next Stage Review for high-quality community care that encourages patient empowerment and self-management. Likewise NICE guidelines (2010) and the Five-Year Forward View (2014) identified the role of the multi-disciplinary team in COPD management.[31,32]
The team includes the primary care nurse, whose assessment and care coordination skills have been described as invaluable in providing advice, education and support to prevent inappropriate hospital admissions.
This supports the view that the primary care nurse is well placed to identify and respond, to enable a patient to ‘do better’ in a condition that is progressive and incurable.[33,34,35]
By Rona Dury
This article was first published on our sister publication Nursing in Practice in March 2017
1. Department of Health. Outcomes strategy for Chronic Obstructive Pulmonary Disease in England. Crown Copyright 2011.
2. Halbert RJ, Natoli JL, Gano A et al. Global burden of COPD: systematic review and meta analysis. Eur Respir 2006;28:523-32.
3. Global Initiative for Chronic Obstructive Lung Disease (2011). Global Strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. goldcopd.org
4. Fletcher M, Dahl B. Expanding nursing practice in COPD: is it key to providing high-quality, effective, and safe patient care? Primary Care Respir J 2013;22:230-2.
5. Palmer, A. Registered Nurse’s Role in COPD care. The Journal of Nursing, 2013. tinyurl.com/zyomsgq
6. Barry MJ. Chronic obstructive pulmonary disease: developing comprehensive management. Respir Care 2003;48:1225-34.
7. Braido F, Balardino I, Sumberesi M et al. Obstructive lung diseases and inhaler treatment: results from a national public pragmatic survey.Respir Res 2013;14-94.
8. WilhelmK, Arnold K, Niven H et al. Grey Lungs and blue moods: smoking cessation in the context of lifetime depression history. Aust NZJ Psychiatry 2004;38:896-905.
9. Ostrowski M. Report takes aim at America’s other drug problem: poor adherence. J Fam Pract 2007;577:734.
10. Rice VH, Stead LF. (2008) Nursing Interventions for smoking cessation (Review) Cochrane database of Systematic Reviews. Issue 1 ART.Doi: 10.1002/14651858.2CD 001188 pub 3.
11. Kant S, Gupta B. Role of Lifestyle in the Development of Chronic Obstructive Pulmonary Disease; A Review. Lung India Apri-Jun; 25:95-101
12. Pauwels RA, Buist AS, Calverley PM et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLB/WHO Global Initiative for Chronic Obstructive Pulmonary Lung Disease (GOLD) Workshop summary Am J Respir Crit Care Med 2001;163:1256-76.
13. Plaza V, Sanchis J. Medical personnel and patient skill in the use of metered dose inhalers; a multicentric study. CESEA Group. Respiration 1998;65:195-8.
14. De Oliveira MA, Bruno VF, Ballini LS et al. Evaluation of an educational program for asthma control in adults. J Asthma 1997;34: 395-403.
15. Matteo B, Usmani O. The importance of inhaler devices in the treatment of COPD Biomed Central The open access publisher. COPD Research and Practice 20151:9 Doi: 10.1186/s40749-015-0011-0.
16. Matuszewski K, Velayudhan P, Flint N et al. Noncompliance with Drug Therapy for Chronic Obstructive Pulmonary Disease: A risk factor for Hospitalization. VALUE in HEALTH 1999;2:446-51.
17. Virchow JC, Crompton GK, Dal Negrp R et al. (2007) Importance of inhaler devices in the management of airway disease. Respiratory Medicine 2008;102:10-19.
18. Corsonello A, Antonelli Incalzi R, Pistelli R et al. Comorbidities of COPD. Current opinion in Pulmonary Medicine 2011;17:21-8.
19. Sabate E, ed. Adherence to long-term therapies. Evidence for Action. World Health Organisation 2003.
20. Steinmann MA, Landefield CS, Rosenthal GE. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc. 2006;54:1516-23.
21. Lareau SC, Yawn BP. Improving adherence with inhaler therapy in COPD. int J Chron Obstruct Pulmon Dis 2010;5:401-6.
22. George J, Kong DC, Thoma R. Factors associated with medication nonadherence in patients with COPD. Chest 2005;128:198-204.
23. Broeders MEAC, Molema J, HOP W C et al. Inhalation profiles in asthmatic and COPD patients: reproducibility and effect of instruction.
J Aerosol Med 2003;16:131-41
24. Palander A, Mattil T, Karka M et al. In vitro comparison of three salbutamol-containing multidose dry powder inhalers. Clin Drug Invest 2000;20:25-33.
25. Raid a M, Al- Showair, Walid Y et al. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respiratory Medicine 2007;101:2395-401.
26. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J 2002;19: 246-51.
27. Wieshammer S, Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration 2008;75:18-25.
28. Laube BL, Janssens HM, de Jongh FH et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir
29. Small M, Anderson P, Vickers A et l. Importance of inhaler-device satisfaction in asthma treatment: real-world observations of physician-observed compliance and clinical/patient-reported outcomes. Adv Ther 2011;28:202-12.
30. Department of Health. The NHS Next Stage Review. DH, 2008.
31. NationaI Institute for Clinical Excellence. COPD and management in over-16s. [CG101] June 2010.
32. Department of Health. The Five-Year Forward Plan. DH 2014.
33. Bodenheimer T. Planned visits to help patients self-manage chronic conditions. Am Fam Physician 2005;72:1454-6.
34. Gore JM, Brophy CJ, Greenstoe MA. How well do we care for patients with end-stage obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax 2000;55:1000-6
35. Public Health Resource Unit. Public Health Skills and Career Framework. PHRU, 2009.